Critical care or intensive care is the close monitoring and treatment given to individuals with acute, life-threatening illness or injuries such as shock, burns, accidents,complicated surgeries, sepsis, and severe breathing problems. It usually takes place in

an ICU or trauma center.The therapeutic usage of drugs during these critical care scenarios are termed as ‘critical care therapeutics’ and can be grouped as below:Plasma therapeutics and Anticoagulants.Several plasma-derived products are commonly used in critical care situations, which include:Albumin,Antithrombin concentrates,Factor XIII concentrates,Fibrinogen concentrates,Prothrombin complex concentrates.

PART 01: Executive summary 6

PART 02: Scope of the report 17

PART 03: Research Methodology 22

PART 04: Introduction 25

Key market highlights 25

The role of plasma therapeutics in critical care industry 27

Introduction to plasma therapeutics 27

Introduction to anticoagulants 35

PART 05: Global critical care therapeutics: Market

landscape 39

Market overview 39

Five forces analysis 45

PART 06: Market segmentation by drug class 46

Global albumin market 46

Global prothrombin complex concentrates market 47

Global antithrombin concentrates market 48

Global factor XIII concentrates market 49

Global fibrinogen concentrates market 50

PART 07: Market segmentation by application 51

DVT 51

Pulmonary embolism (PE) 51

Acute coronary syndrome 51

Atrial fibrillation 51

Hemodialysis 51

Coronary angioplasty 52

Surgeries 52

PART 08: Geographical segmentation 53

Critical care therapeutics market in Americas 55

Critical care therapeutics market in EMEA 58

Critical care therapeutics market in APAC 61

PART 09: Market drivers 64

High demand for albumin in China 64

Increasing surgical procedures 65

Growing preference for marketed products over

alternative treatment options 65

Impact of drivers 66

PART 10: Market challenges 67

Existence of plasma fractionation supply and demand

gap 67

Spread of pathogenic contaminants 68

High regulations of plasma products 68

PART 11: Impact of drivers and challenges 69

PART 12: Market trends 70

Increased development of recombinant products for

critical care use 70

Establishment of plasma fractionation facilities in

emerging economies by global players 71

Strategic initiatives of vendors fueling the market

growth 71

PART 13: Vendor landscape 73

Competitive scenario 73

Other prominent vendors 77

PART 14: Key vendor analysis 83

CSL Behring 83

Grifols 85

Kedrion Biopharma 89

Octapharma 91

Shire 94

PART 15: Appendix 97

List of abbreviations 97

PART 16: Explore Technavio 100